EGFR and non-small cell lung carcinoma: To date, only two PCR-based liquid biopsy tests have FDA approval as companion diagnostic assays for selecting TKI treatment in EGFR-mutated NSCLC (i.e., Cobas® EGFR Mutation Test v2 and Therascreen® EGFR RGQ PCR) [26].